Patents by Inventor Gregory S. Ducker

Gregory S. Ducker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11759453
    Abstract: The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: September 19, 2023
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Patent number: 11369588
    Abstract: A 10-formyl-THF pathway for producing NADPH is useful in the diagnosis and treatment of cancer and metabolic disease, in the development of new antineoplastic agents and/or regimens, in the development of new methods for measuring metabolic pathway activity, and in the development of new therapeutics for treating metabolic disease.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: June 28, 2022
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Jing Fan, Gregory S. Ducker
  • Patent number: 10934305
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 2, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Publication number: 20200239488
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmue disorders.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Publication number: 20200237725
    Abstract: The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.
    Type: Application
    Filed: April 7, 2020
    Publication date: July 30, 2020
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Patent number: 10646475
    Abstract: The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 12, 2020
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Patent number: 10584132
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmue disorders.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: March 10, 2020
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Publication number: 20180354964
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmue disorders.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Patent number: 10077273
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 18, 2018
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Publication number: 20180117010
    Abstract: The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.
    Type: Application
    Filed: March 10, 2016
    Publication date: May 3, 2018
    Inventors: Joshua D. RABINOWITZ, Hahn KIM, Gregory S. DUCKER, Jonathan M. GHERGUROVICH
  • Publication number: 20180072751
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.
    Type: Application
    Filed: September 14, 2017
    Publication date: March 15, 2018
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Publication number: 20170000769
    Abstract: A 10-formyl-THF pathway for producing NADPH is useful in the diagnosis and treatment of cancer and metabolic disease, in the development of new antineoplastic agents and/or regimens, in the development of new methods for measuring metabolic pathway activity, and in the development of new therapeutics for treating metabolic disease.
    Type: Application
    Filed: September 15, 2016
    Publication date: January 5, 2017
    Applicant: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Jing Fan, Gregory S. Ducker